Navigation Links
New Data on Cimzia® (certolizumab pegol) to be Presented at ACG Meeting Highlights Role of Inflammatory Biomarkers in Treatment for Moderate to Severe Crohn's Disease
Date:10/31/2011

re taking concomitant immunosuppressants such as methotrexate or corticosteroids.  CIMZIA should be discontinued if a patient develops a serious infection or sepsis.  Reported infections include:

  • Active tuberculosis, including reactivation of latent tuberculosis.  Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.  Patients should be tested for latent tuberculosis before CIMZIA use and during therapy.  Treatment for latent infection should be initiated prior to CIMZIA use.  
  • Invasive fungal infections, including histoplasmosis , coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.  Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.  Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection.  Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness .
  • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.  Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with CIMZIA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member.  CIMZIA is not indicated for use in pediatric patients.

Patients treated with CI
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
2. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
3. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
4. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
5. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
6. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
7. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
8. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
9. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
10. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
11. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Reportlinker.com announces that a ... catalogue: mHealth and Home Monitoring – ... Executive summary mHealth can ... better outcomes, decreased costs and improved sustainability of ... is still in an early stage, but on ...
(Date:7/30/2014)... and KISSING, Germany , ... distributor of a single use and computer-assisted ("robotic") colonoscopy ... Shamir , a worldwide recognized medical device executive, as ... Mr. Shamir is a highly respected global visionary ... assignment he served as President and Chief Executive Officer ...
(Date:7/30/2014)... DIEGO , July 30, 2014  Eisai Inc. and ... that an article based on post-hoc analyses from the three ... While on Lorcaserin, Diet, and Exercise as a Predictor of ... issue of Obesity , the official peer reviewed journal ... to identify whether there is an early treatment milestone that ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Global safety equipment manufacturer MSA (NYSE: MSA ... air-purifying respirator (APR) line in two U.S. factories in ...  The respirators, which include half-mask and full-facepiece models, are ... health officials involved with remediation and containment efforts associated ...
... March 30, 2011 Generex Biotechnology Corporation ( www.generex.com ... a press conference earlier today at the NASDAQ Marketsite ... plan for the Company,s future growth.  A video of ... Generex website. (Logo: https://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) ...
Cached Medicine Technology:MSA Increases Production of Air-Purifying Respirators to Help Meet Increased Demand from Japan 2Generex Unveils Strategic Development Plan 2Generex Unveils Strategic Development Plan 3Generex Unveils Strategic Development Plan 4Generex Unveils Strategic Development Plan 5Generex Unveils Strategic Development Plan 6Generex Unveils Strategic Development Plan 7Generex Unveils Strategic Development Plan 8Generex Unveils Strategic Development Plan 9
(Date:7/30/2014)... 30, 2014We have pills to ease pain, to cure infection, ... to enhance our sexual and athletic prowess. Why do pills ... we benefit from taking fewer pills? This provocative topic is ... and Fantasy of Pills in Modern Medicine ," published in ... peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article ...
(Date:7/30/2014)... Today, Gen. Arthur T. Dean, Chairman ... (CADCA) , the nation’s leading substance abuse prevention organization, ... New York Times Editorial Board’s call for marijuana ... , “CADCA is disappointed in the New York Times ... marijuana legalization. The move is shortsighted and completely disregards ...
(Date:7/30/2014)... 2014 (HealthDay News) -- Medical costs for chronic obstructive ... than $32 billion each year, according to new research ... The yearly financial toll of COPD (which includes ... estimated $49 billion by 2020. "For the first ... provide state public health practitioners with estimates of the ...
(Date:7/30/2014)... The Europe Phytochemicals & plant extracts market ... market in Europe with analysis and forecast of revenue. ... estimated to grow from around 710.18$ million in 2012 ... 8.4%, for the given period. , Browse through the ... report, to get an idea of the in-depth analysis ...
(Date:7/30/2014)... could help doctors decide which bladder cancer patients would ... according to a study* published in the British ... The University of Manchester, funded by the Medical Research ... levels of a protein, called ,HIF-1α, were more likely ... carbon dioxide gas and nicotinamide tablets at the ...
Breaking Medicine News(10 mins):Health News:CADCA Responds to New York Times Editorial Board's Call for Marijuana Legalization 2Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Phytochemicals & Plant Extracts (Nutraceuticals) Market is Expected to Reach $1,150.64 Million in 2018 - New Report by MicroMarket Monitor 5Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2
... team of researchers at the John Hopkins Hospital in the US ... the PSA to detect prostate cancer.// ,The new test ... a simple blood test. ,Prostate cancer, the most ... of medicine. Physicians are unsure how to find it and when ...
... Thirteen year olds can perform cardiopulmonary resuscitation (CPR) as ... today. The authors suggest that children as young as ... chest compressions. ,Bystander CPR more than doubles ... arrest. Chest compressions are thought to be the most ...
... At least one-third of the time, the symptoms of ... in children, it can be difficult //to distinguish bipolar ... 2007 issue of the Harvard Mental Health Letter. ... the adult cycle of distinct mood episodes of mania ...
... are similar or better than those of whites when differences ... published in the American Heart Journal, Reuters reports. ... Rogers Memorial Veterans Hospital and colleagues studied the care and ... who were treated at five VA hospitals. ...
... Ahmed Obaid, Under-Secretary General and Executive Director of the ... Regional Director of UNFPA have// pressed the need for ... the highest maternal mortality rate in the world. More ... improve the health of the women and children. ...
... of the HIV eradication potential of a bone marrow transplant ... concluded that// eradication is unlikely utilising this method. ... reduce HIV to 'undetectable' levels in the blood, but they ... of our own cells. Although scientists have been working on ...
Cached Medicine News:Health News:New blood test to detect prostate cancer 2Health News:Priority Needs to Be Given to Maternal Health in Afghanistan 2Health News:HIV Eradication Unlikely Following Bone Marrow Transplantation 2Health News:HIV Eradication Unlikely Following Bone Marrow Transplantation 3
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... multichannel has the same innovative ... model. The same universal handle ... five single channel tip cone ... recharge and storage stand with ...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
... Comfort Pick one of our pipettors up ... trigger and ejector positionsright where they should beeven ... ergonomically designed to help avoid repetitive stress injuries ... In The Palm Of Your Hand Start ...
Medicine Products: